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Abstract 
Hypersensitivity reactions to particulate drugs can partly be caused by complement activation 
and represent a major complication during intravenous application of nanomedicines. Several 
liposomal and micellar drugs and carriers, as well as therapeutic antibodies, were shown to 
activate complement and induce complement activation-related pseudoallergy (CARPA) in 
model animals. To explore the possible use of the natural complement inhibitor factor H (FH) 
against CARPA, we examined the effect of FH on complement activation induced by 
CARPAgenic drugs. Exogenous FH inhibited complement activation induced by the 
antifungal liposomal Amphotericin-B (AmBisome), the widely used solvent of anticancer 
drugs Cremophor EL, and the anticancer monoclonal antibody rituximab in vitro. An 
engineered form of FH (mini-FH) was more potent inhibitor of Ambisome-, Cremophor EL- 
and rituximab-induced complement activation than FH. The FH-related protein CFHR1 had 
no inhibitory effect. Our data suggest that FH or its derivatives may be considered in the 
pharmacological prevention of CARPA. 
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Introduction 
Hypersensitivity reactions, which may have various underlying mechanisms, represent a 
substantial medical problem during intravenous (i.v.) application of certain nanoparticle-
containing medicines.1-3 Premedication with steroids and other anti-allergic medicines can 
reduce the risk and severity of such adverse reactions; however, prevention by inhibiting the 
triggering mechanisms, e.g. complement activation, is expected to offer more specific and 
effective measure against this adverse immune effect.3-6 
 Complement activation can underlie acute, non-IgE-mediated allergic (infusion) 
reactions to particulate drugs, which reactions can occasionally be severe, or even lethal.1,3 
Thus, this phenomenon represents a major immune barrier to the therapeutic use of many 
state-of-the-art “nanomedicines”, such as liposomal and micellar drugs and therapeutic 
antibodies.3,7 This so-called complement activation-related pseudoallergy (CARPA) is 
characterized by severe cardiopulmonary changes including arrhythmia, pulmonary edema, 
hypotension, airway occlusion, respiratory distress and cardiac arrest that in serious cases can 
cause anaphylactic cardiogenic shock and death.3 Activation of the complement system leads 
to the formation of the anaphylatoxins C3a and C5a that can trigger mast cells and basophils 
to release a variety of secondary mediators with potent pathophysiological actions.3,8 Among 
these mediators, histamine, thromboxane A2 and platelet-activating factor have been shown to 
be causally involved in CARPA due to liposomes.3 
Complement is a main humoral defense system of innate immunity against infectious 
microbes. It also plays an important role in the removal of immune complexes and dying 
cells, and modulates the activation of cells of the innate and adaptive immune systems.8 
Complement constantly probes surfaces and can be activated via three major pathways, the 
classical, the lectin and the alternative pathway (Figure 1A). The alternative pathway (AP) is 
continuously activated at a low level and, independent of the initial activation route, it 
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provides strong amplification of the system, because the central C3b molecule, generated by 
any pathway, forms the C3bBb AP C3 convertase that cleaves additional C3 molecules into 
the anaphylatoxin C3a and the opsonin C3b. C3b binding to the C3 convertases shifts the 
ligand specificity of these enzymes that then gain the ability to cleave C5 into C5a and C5b. 
C5a is a potent anaphylatoxin and inflammatory mediator. C5b initiates the terminal pathway, 
leading to the formation of the C5b-9 terminal complement complex, which when formed in 
cell membranes (then termed membrane attack complex, MAC) may cause cell lysis. 
Adverse effects of complement in the host, due to overactivation or activation on 
inapproptiate surfaces and ligands, are prevented by cell membrane-bound and soluble 
complement inhibitory molecules, which control this system at several check points. Factor H 
(FH) is one of the main soluble complement regulators.9-11 This 155-kDa glycoprotein has an 
average plasma concentration of approximately 260 µg/ml. It is composed of 20 complement 
control protein (CCP) domains, of which CCPs 1-4 mediate the complement inhibiting 
function of FH and CCPs 19-20 mediate the docking of FH to certain host surfaces, such as 
basement membranes and endothelial cells (Figure 1B). Thus, FH inhibits complement 
activation not only in the body fluids but on host surfaces, too.11 FH regulates complement at 
the AP C3 convertase level by preventing the formation of the C3bBb convertase, by 
facilitating its dissociation if already formed, and by assisting the protease factor I in the 
enzymatic inactivation of C3b. These activities render FH a potent down-regulator of 
complement activation (Figure 1A). 
The antifungal drug, liposomal Amphotericin-B (AmBisome) and paclitaxel (Taxol), a 
widely used anticancer drug solubilized by Cremophor EL (CrEL) micelles, were shown to 
activate complement partly via the AP, and to induce CARPA in pigs with symptoms 
mimicking the human anaphylactic reaction to these drugs.12,13 Various therapeutic antibodies 
also cause hypersensitivity reactions.3,6 Thus, it was hypothesized that inhibition of AP 
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complement activation might interfere with the CARPAgenic activity of these drugs. 
Therefore, our aim was to assess the capacity of the natural AP regulator FH and its 
engineered derivative mini-FH to inhibit complement activation induced by AmBisome, CrEL 
and the therapeutic antibody rituximab in vitro. 
 
 
Methods 
Proteins, reagents and sera 
Purified human FH was from Merck (Budapest, Hungary). Recombinant constructs covering 
FH CCP1-4 (FH1-4), CCP15-20 (FH15-20), CCP1-4 and CCP19-20 (Mini-FH), and CFHR1 
were produced in insect cells as described.14,15 
CrEL and zymosan (Zymosan-A) were from Sigma-Aldrich Ltd. (Budapest, Hungary), 
AmBisome was purchased from Gilead Sciences Ltd. (Paris, France), and rituximab (Rituxan; 
Roche, UK) was obtained from a local pharmacy. 
Blood withdrawal and experimentation were performed with approval of the 
respective research ethics committee and in accordance with the Declaration of Helsinki. 
Blood donors were healthy Caucasian volunteers and gave informed consent. Peripheral blood 
was collected in BD Vacutainer® (BD, Franklin Lakes, NJ) serum tubes, allowed to clot at 
4oC for 10 min, and after centrifugation aliquots of normal human serum (NHS) were stored 
at -80°C. 
 
Preparation of liposomes 
The liposomes were prepared using the extrusion method. Cholesterol (Solvay 
Pharmaceuticals, Brussels, Belgium), hydrogenated soy phosphatidyl choline (HSPC) and 
1,2-distearoy l-phosphatidyl ethanolamine-methyl-polyethyleneglycol conjugate-2000 
(DSPE-mPEG2000) - all from Lipoid GmbH (Ludwigshafen, Germany) - were dissolved in 
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alcohol, mixed in molar ratios as described in Table 1, then 250 mM ammonium sulfate 
(Sigma-Aldrich) was added to the mix. The multilamellar vesicle (MLV) particles were 
extruded to uniform particle size distribution on membrane filter (Thermo Fisher Scientific 
Inc., Waltham, MA, USA) by means of a Lipex™ Extruder (Northern Lipids Inc., Burnaby, 
B.C. Canada). The liposomes were dialyzed against 10% sucrose/10 mM His, pH 7.4 buffer 
(Sigma-Aldrich) and diluted (volume ratio of 1:1) in the same buffer after dialysis. The size 
was determined by Malvern Zetasizer Nano S (Malvern Instruments Ltd, Malvern, UK). 
Liposomes containing cholesterol-anchored PEG2000 (Chol-2P)16 was obtained from Utrecht 
Institute for Pharmaceutical Sciences (Utrecht University, The Netherlands). 
 
Complement activation assays 
CrEL was diluted to 105.4 mg/ml and zymosan to 1.5 mg/ml with phosphate buffered saline 
(PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4). AmBisome 
was diluted to 20 mg/ml with sterile water. FH or the recombinant complement inhibitors, 
diluted in PBS in 5 µl, were mixed with 15 µl NHS, then 5 µl of the AmBisome, zymosan or 
CrEL dilutions were added, and incubated for 45 min at 37°C in a heated shaker. Rituximab 
(in 75 µg/ml or 300 µg/ml final concentration) and the complement inhibitors FH and mini-
FH (both in 1.3 µM final concentration) in PBS were added to whole blood containing 
lepirudin as anticoagulant in microcentrifuge tubes (in a final volume of 300 µl, containing 
50% blood), vortexed and incubated for up to 300 minutes at 37oC. SC5b-9 in the supernatant 
after centrifugation for 10 min at 1750 g was measured using a commercial kit (TECOmedical 
AG, Sissach, Switzerland), according to the protocol provided by the manufacturer. 
 
B cell survival assay 
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Human tonsil B cells were isolated as previously described.17 BL-41 lymphoma cells were 
cultured in RPMI-1640 medium supplemented with 100 U/ml penicillin, 100 μg/ml 
streptomycin and 10% fetal calf serum. 2 × 106 B cells per sample were incubated in veronal 
buffered saline (VBS; 5 mM veronal, 145 mM NaCl, 0.15 mM CaCl2 and 0.5 mM MgCl2, pH 
7.3) or 50% NHS diluted in VBS in 100 μl final volume. Rituximab was added at 10 μg/ml. In 
preliminary experiments, this concentration showed saturation of binding to B cells (measured 
by flow cytometry), and there was no increase in complement-mediated cell lysis when higher 
concentrations were used. The complement inhibitors FH and FH1-4 were added at 1.3 μM 
concentration. After incubation at 37°C for 30 min, dead cells were stained with propidium 
iodide (PI). 10,000 cells were analyzed in each sample using a FACSCalibur flow cytometer 
and CellQuest software for data acquisition (BD Biosciences, Heidelberg, Germany). Data 
analysis was performed using FlowJo (Tree Star, Ashland, OR) software. 
 
 
Results 
 
FH and mini-FH inhibit AmBisome- and CrEL-induced complement activation 
To assess the efficacy of FH to inhibit liposome-induced complement activation, human 
serum samples were incubated with AmBisome with or without the addition of exogenous FH 
at the concentration of 200 µg/ml (~1.3 µM). This amount of FH approximately doubles the 
physiological FH concentration. SC5b-9 was detected because it is a quite stable end-product 
of complement activation, can be reliably measured, and is generated in parallel with C5a that 
is involved in the CARPAgenic effect. Serum or buffer alone resulted in baseline SC5b-9 
formation, whereas AmBisome significantly increased the amounts of soluble SC5b-9. 
Exogenous FH strongly and significantly reduced AmBisome-induced formation of SC5b-9 
(Figure 2A). Zymosan, a yeast cell wall extract and well-known activator of the complement 
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AP, was used as a positive control. Zymosan at 0.3 mg/ml concentration strongly activated 
complement and enhanced the formation of SC5b-9 in serum, which was slightly, but not 
significantly, inhibited by FH under the studied conditions (Figure 2A). 
To further analyze the capacity of FH to inhibit liposome-induced complement 
activation, liposomes of various composition were prepared, which differed in the amounts of 
PEG incorporated and, accordingly, caused various degrees of SC5b-9 increase when added 
to human serum. In all cases, addition of 1.3 µM FH reduced SC5b-9 to the background level 
(Figure 2B). This is likely due to the lower level of SC5b-9 induced compared with 
AmBisome (Figure 2A). 
Previously, we described mini-FH, an artificial complement inhibitor that combines 
the N-terminal complement regulatory domains (CCPs 1-4) and the C-terminal C3b- and 
polyanion binding domains (CCPs 19-20) of FH (Figure 1).15 In our experiments, mini-FH 
also inhibited complement activation induced by AmBisome, and its effect was more 
pronounced in comparison with FH (Figure 3A). Similar to this, FH and mini-FH inhibited 
complement activation induced by CrEL-micelles (Figure 3B). The inhibitory effect was 
dose-dependent (Figure 3C), and the extent of inhibition suggested that mini-FH is on a 
molar basis approximately twofold more potent inhibitor of complement activation under 
these conditions than FH (compare Figures 3A and 3C), because 0.65 µM mini-FH reduced 
SC5b-9 to similar level as did 1.3 µM FH. 
 
Evaluation of functional domains of FH and the FH-related protein CFHR1 
While CCPs 1-4 of FH (FH1-4) are necessary and sufficient to control complement activation 
in fluid phase, CCPs 19-20 of FH are responsible for recognition of surface-deposited C3b 
and surface polyanionic molecules, and can direct FH to specific host surfaces.18-21 Therefore, 
we tested if a FH1-4 construct can inhibit complement activation induced by liposomes and 
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CrEL micelles similar to FH. To this end, complement activation in human sera was induced 
by AmBisome or CrEL, in the presence of equimolar amounts (1.3 µM) of FH, FH1-4 or 
FH15-20. FH1-4 was less potent in inhibiting AmBisome- (Figure 4A) and CrEL-induced 
(Figure 4B) increase of serum SC5b-9 than FH, indicating that the full-length molecule is 
more active. Thus, the native conformation of full-length FH and/or its binding to the 
activating surface may be important to optimally reduce complement activation. FH15-20, 
which lacks the complement regulatory domains of FH, did not inhibit either AmBisome- or 
CrEL-induced complement activation. 
 In addition, we investigated whether the FH-related CFHR1 protein, which had been 
described as a terminal complement pathway inhibitor,22 influenced the formation of SC5b-9 
in our assays. CFHR1 when added at 1.3 µM concentration (~50 µg/ml; estimated CFHR1 
plasma concentrations are 40 µg/ml23 and 70-100 µg/ml22) did not inhibit SC5b-9 generation 
induced by either AmBisome (Figure 4A) or CrEL (Figure 4B). 
 
FH and mini-FH inhibit rituximab-induced complement activation in vitro 
A significant proportion of patients suffer adverse reactions caused by therapeutic antibodies, 
even if premedication is provided.3,6 Rituximab, a widely used anti-CD20 mAb caused 
complement activation in anti-coagulated whole blood, more so when lepirudin was used as 
anticoagulant, compared to heparin (Figure 5A). FH inhibited complement activation induced 
by rituximab (Figure 5B). At higher, 300 µg/ml rituximab concentration, however, 1.3 µM 
FH was not effective. Mini-FH strongly inhibited rituximab-induced complement activation, 
even at 300 µg/ml rituximab (Figure 5B). 
When the mechanism of action of a therapeutic antibody involves complement-
dependent cytotoxicity, such as in the case of rituximab, it is important not to interfere with 
complement activation on the target cell curface. We therefore compared the effect of the 
same amounts of FH and the FH1-4 construct, which does not bind to cells, on survival of 
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human B cells in the presence of rituximab and serum. FH strongly, whereas FH1-4 only 
marginally increased the number of surviving primary tonsil B cells (Figure 6A) and BL-41 
lymphoma cells (Figure 6B) when incubated with rituximab in the presence of human serum. 
Thus, FH1-4 may be considered to inhibit fluid-phase (i.e. serum) complement activation 
without interfering with the complement-mediated lytic effect of the therapeutic mAb on 
target B cells. 
 
 
Discussion 
After the discovery of the CARPA phenomenon, the application of complement inhibitors to 
ameliorate this adverse reaction was suggested,24 and strategies to anchor complement 
inhibitor proteins or their active fragment to membranes, e.g. via a myristoyl group carrying 
the CCP1-3 of complement receptor type 1, were reported.25,26 Nanomedicines can cause 
complement activation via various pathways, and theoretically each of these activation 
pathways could specifically be inhibited by a suitable inhibitor, e.g. C1 inhibitor for the 
classical/lectin pathways. We aimed to investigate an inhibitor that could likely be more 
broadly used. Because FH is a major inhibitor at the level of the central C3 complement 
component and that of the AP amplification loop (Figure 1A), it is an ideal regulator to 
reduce or even prevent generation of the C3a and C5a anaphylatoxins, and also that of C5b-9, 
particularly, because complement activation by any pathway would be amplified through this 
loop.8-11,27 In addition, it was reported that FH could inhibit the classical pathway on ligands 
where FH can compete for binding with C1q,28 which may also play a role in the case of 
certain nanomedicines. The results of our current study demonstrate that FH is a potent 
inhibitor of complement activation induced by liposomes, CrEL micelles and rituximab in 
serum in vitro.  
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FH does not only act in fluid phase but is also an effective and important complement 
inhibitor on surfaces where FH is able to bind, such as host basement membranes and cells, 
but in many cases also foreign structures such as pathogens, that sequester host FH to evade 
the action of complement.11 We observed that the full-length FH molecule was a better 
inhibitor of complement activation induced by both AmBisome and CrEL than the FH 
fragment (FH1-4) containing only the regulatory domains CCPs 1-4 of the molecule (Figure 
4). This suggests that the native conformation of the full-length molecule is important to 
optimally inhibit complement, and/or that FH is able to bind to the surface of liposomes and 
micelles and locally downregulate complement activation. Indeed, recently FH binding to 
liposomal membranes was demonstrated.29 Naturally, the complement regulatory CCPs 1-4 
are important for the inhibitory effect, and CCPs 19-20 harbour binding sites for both surface-
bound C3b/C3d and glycosaminoglycans (or some other ligands).11 The latter domains may 
mediate binding of FH, depending on the amount and nature of C3b fragments (C3b, iC3b, 
C3d) present on the surface. However, inhibition of complement activation in our assays does 
not necessarily require surface binding of FH, because significant inhibition was obtained 
with FH1-4. 
Derivatives of FH are being evaluated as potential therapeutic complement inhibitors, 
including the mini-FH class of molecules.15,27,30 The two reported, slightly differing mini-FH 
molecules have FH CCPs 1-4 fused with CCPs 19-20, and were shown to have enhanced 
complement inhibiting capacity compared to the full-length FH.15,30 A third mini-FH version 
contains CCPs 1-5 and CCPs 18-20, has also superior complement inhibiting activity over 
FH, and showed its efficacy in reducing C3 turnover also in vivo.31 The enhanced activity of 
mini-FH is likely due to the increased availability of the C-terminal glycosaminoglycan/C3d 
binding sites in the shorter molecules, which are probably partly hidden in the full-length FH. 
In agreement with these previous results using different types of complement activation 
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assays, on a molar basis mini-FH was more active than FH in preventing liposome- and 
rituximab-induced complement activation (Figures 3 and 5). Thus, engineered FH-
derivatives may prove useful to effectively down-regulate such adverse complement 
reactions. While mini-FH in its current form, owing to its small size, is rapidly cleared from 
the circulation, it still could be useful especially to inhibit CARPA, which is a relatively 
quickly arising adverse reaction and thus the short-term inhibitory effect of mini-FH, when 
co-administered with or even coupled to the potentially CARPA-genic drug, could be 
satisfactory to prevent or reduce CARPA. 
The background mechanism and the extent of complement activation differ due to the 
various composition, surface charge, size and physical properties etc. of the liposomes, 
micelles and other nanocarriers.3 The amount and nature of deposited C3 fragments, as well 
as the physico-chemical properties of the surfaces, also influence the potential interaction of 
FH with these surfaces. These at least in part explain why the same amount of tested FH 
resulted in different degree of inhibition; for example, the stronger complement activation and 
thus higher SC5b-9 levels induced by AmBisome could only partially be inhibited by FH and 
completely by mini-FH, whereas in the case of CrEL, the less amount of SC5b-9 was fully 
inhibited by both FH and mini-FH, both applied in 1.3 µM in the assays (Figure 3). 
Altogether these results suggest that an engineered mini-FH-like derivative of FH could be 
more useful for inhibitory purposes than the native molecule, because it is a more potent 
complement inhibitor and can also be produced in a more controlled way.15  
The FH-related CFHR1 protein was previously described as a novel complement 
inhibitor that binds to C5 and down-regulates the terminal pathway,22 which effect could not 
be confirmed by other investigators.32-35 We tested recombinant CFHR1 for its capacity to 
influence SC5b-9 formation in the liposome- and CrEL-induced complement activation 
assays in vitro and found no inhibitory effect of this FH-related protein (Figure 4). While this 
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does not exclude a potential of CFHR1 to regulate cell membrane integrated C5b-9, these 
results question a general terminal pathway inhibiting function of the protein. 
Hypersensitivity or infusion reactions, mediated in part by complement activation, can 
be observed in a substantial number of patients when administering therapeutic mAbs.6 
Although such reactions do not affect every patient, reactions to various extent were reported 
in the case of the different mAbs (from <1% to over 50%), and even fatal reactions occur.36 
For rituximab, adverse reactions were reported in up to 85% of patients, with 2-10% being 
severe reactions and 0.04-0.07% being fatal.37 In our assays, FH and mini-FH were able to 
reduce or inhibit rituximab-induced complement activation in serum in vitro (Figure 5). This 
is most likely due to fluid-phase inhibition of complement activation by FH and mini-FH. 
The mechanism of action of rituximab on the target B cells involves complement-
dependent lysis, antibody-mediated cellular cytotoxicity and induction of apoptosis; however, 
it is still unknown which of these is the most important mechanism.38 FH when bound from 
serum to the cells can reduce the efficacy of complement-mediated B cell killing due to its 
inhibitory nature.39 We found, however, that FH1-4, which can be used to inhibit complement 
activation in serum (Figure 4) but cannot bind to the cell surface, does not substantially 
decrease the efficiency of surface-bound rituximab to induce complement-mediated killing of 
B cells (Figure 6). 
There are differences among individuals in the rate of complement activation, which is 
influenced by serum levels and functional variants of complement proteins and regulatory 
molecules, such as those of FH. For example, the FH level varies substantially among 
individuals (124.4-402 µg/ml).40 The specific set of complement gene variants, termed 
complotype, determines how quickly and to what extent complement activation occurs under 
given circumstances in serum of a person, and influences the risk to inflammatory and 
infectious diseases.41 This likely explains the observed differences in AmBisome- and CrEL-
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induced SC5b-9 production in the sera of the various donors (Figures 3 and 4). While genetic 
analysis to determine the complotype and measurement of protein levels are time-consuming 
and costly, the capacity of given nanomedicines to induce complement activation in serum or 
blood of a patient can be tested relatively easily in a functional assay, as also shown here.42,43 
In summary, our data suggest that FH or its derivatives like mini-FH could be a 
potentially useful approach to prevent complement activation and thus CARPA caused by a 
variety of nanomedicines, monoclonal antibodies and other agents. When the mechanism of 
action of a therapeutic antibody involves complement-dependent cytotoxicity, such as in the 
case of rituximab, a FH construct that does not bind to cells, e.g. FH1-4, may be considered. 
Importantly, with a relatively simple test patients can be pre-screened for proneness for 
CARPA and thus a complement inhibitor may be applied when indeed necessary.42,43  
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Figure legends 
 
Figure 1. Figure showing the point of action of FH in the complement system and 
schematic drawing of FH and the used recombinant proteins. 
(A) Simplified overview of the complement cascade. Complement activation can be initiated 
via three pathways, the classical, lectin and alternative pathway. These merge at the central 
component C3, which is cleaved into C3a and C3b. The latter forms the basis of the 
amplification loop of the alternative pathway and also initiates the terminal pathway. The 
serum complement inhibitor FH helps the inactivation of C3b and the dissociation of the 
enzyme necessary for C3b generation. 
(B) FH consists of 20 complement control protein (CCP) domains. Mini-FH, a recombinant 
construct contains only the main functional domains of FH (CCPs 1-4 and 19-20).15 FH 
constructs used in the experiments were FH1-4, which contains the CCPs 1-4, and FH15-20 
consisting of CCPs 15-20. Factor H-related protein 1 (CFHR1) is composed of five domains 
that are shown aligned with the homologous FH domains. The numbers above the CFHR1 
domains show the amino acid sequence identity in % to the corresponding FH domains. GAG, 
glycosaminoglycan. 
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Figure 2. Factor H (FH) inhibits AmBisome-induced complement activation. 
(A) Complement activation was measured in normal human sera by assessing the formation of 
SC5b-9 with ELISA. As positive control, we used zymosan A, which strongly activates 
complement. AmBisome (AmBi) caused significant, ~8-fold rise of SC5b-9 over baseline, 
although this rise was less than that caused by zymosan A. Exogenous FH, added at 200 
µg/mL (1.3 µM) concentration, led to >50% inhibition of liposome-induced complement 
activation. FH slightly but non-significantly reduced zymosan-induced complement 
activation. 
(B) Liposomes of various compositions were prepared as described in Methods and Table 1, 
and caused various degrees of complement activation when added to normal human sera as in 
(A). FH was added at 1.3 µM concentration. Chol-2P: liposomes containing cholesterol-
anchored PEG2000.16 
Data are mean + SEM of at least three measurements. *, p < 0.05, **, p < 0.01 and ***, p < 
0.001, Student’s t-test. ns, not significant. 
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Figure 3. Mini-factor H (mini-FH) more strongly inhibits drug-induced complement 
activation compared with full-length factor H (FH). 
Complement activation was measured in five (A) and six (B) normal human sera by assessing 
the formation of SC5b-9 with ELISA. Both AmBisome (A) and Cremophor EL (B) caused 
significant increase of SC5b-9. Exogenous FH, added at 1.3 µM concentration, significantly 
reduced SC5b-9 formation. Mini-FH,15 a recombinant compact form of factor H consisting 
only the main complement inhibitory domains (CCPs 1-4) and surface recognition domains 
(CCPs 19-20), added also at 1.3 µM concentration, more potently inhibited SC5b-9 
generation compared with FH. Serum only: no Ambisome/CrEL added.  Data are mean + 
SEM, *, p < 0.05, and ***, p < 0.001 (ANOVA).  
(C) Ambisome was added to serum alone (PBS) or together with increasing concentrations 
(0.32-1.3 µM) of mini-FH, as indicated. Serum only: no Ambisome added. SC5b-9 was 
measured by ELISA. Data are mean + SEM from experiments with five human sera. *, p < 
0.05, and ***, p < 0.001 (ANOVA).  
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Figure 4. Evaluation of factor H fragments FH1-4 and FH15-20, and the factor H-
related protein CFHR1. 
Complement activation was measured in 3 normal human sera by assessing the formation of 
SC5b-9 with ELISA. Recombinant FH1-4, FH15-20, and the FH-related protein CFHR1 were 
tested for their capacity to inhibit complement activation induced by AmBisome (A) and 
Cremophor EL (B) in 3 normal human sera in the presence of the various proteins at 1.3 µM 
concentration by measuring the formation of SC5b-9 with ELISA. For comparison and as a 
positive control, the inhibitory effect of exogenous FH was also tested at 1.3 µM 
concentration. Serum only: no Ambisome/CrEL added. Data are mean + SEM, *, p < 0.05, 
and **, p < 0.01 (ANOVA).  
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Figure 5. Factor H (FH) and mini-FH inhibit rituximab-induced complement activation. 
 (A) Rituximab induces complement activation in anti-coagulated whole blood. Whole blood 
assay was performed by addition of 300 µg/ml rituximab for the indicated time. In samples 
with lepirudin, an anticoagulant not interfering with complement activation, a rise in SC5b-9 
can be observed compared with samples with heparin. A representative experiment is shown 
perfomed with three blood samples. Significantly higher concentration of SC5b-9 can be 
detected upon addition of rituximab in samples with lepirudin compared with those with 
heparin (p = 0.0002, Student’s t-test). 
 (B) Rituximab was added in the indicated concentrations to whole blood containing 
lepirudin. FH and mini-FH were added at 1.3 µM concentration, and SC5b-9 was measured 
by ELISA. Data are mean + SEM of experiments with three blood donors. *, p < 0.05, and ns, 
not significant (ANOVA).  
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Figure 6. Effect of FH and FH1-4 on the survival of rituximab-treated B cells in human 
serum. Tonsil B cells (A) or BL-41 lymphoma cells (B) were incubated in 50% NHS. 
Rituximab was added at 10 µg/ml and the complement inhibitors were added in 1.3 µM 
concentration. Percentage of living cells after treatment is indicated. Dead cells are identified 
as propidium iodide (PI)-positive, and living cells as PI-negative cells. VBS, veronal buffered 
saline; RTX, rituximab; NHS, pooled normal human serum; FH, factor H; FH1-4, 
recombinant FH domains CCP1-4. 
 
26 
 
Table 1. Composition of the various liposomes used in this study. 
Liposome 
ID 
Compositon 
(Chol:PEG:HSPC) 
Extrusion 
Size 
(d.nm) 
4901S MLV 39:0:61 no 269.5 
4901S SUV 39:0:61 yes 102.4 
4902S MLV 39:5:56 no 530.1 
4902S SUV 39:5:56 yes 82.8 
4903S MLV 39:10:51 no 323.4 
4903S SUV 39:10:51 yes 69.3 
 
MLV, multilamellar vesicle; Chol, cholesterol; PEG, polyethyleneglycol; HSPC, 
hydrogenated soy phosphatidyl choline 
 
 
